Alternative Treatments for Patients with Elevated LDL and Statin Side Effects

First-Line Alternative: Ezetimibe

Ezetimibe works through a complementary mechanism by inhibiting cholesterol absorption in the intestine, providing 15-20% additional LDL-C reduction 1

Bile acid sequestrants can be considered as an alternative if patients are ezetimibe-intolerant, particularly when triglycerides are low, according to the American College of Cardiology 1, 2
For patients with severe hypercholesterolemia or very high cardiovascular risk who cannot tolerate statins, PCSK9 inhibitors can provide substantial LDL-C lowering (50-60%) 3, 1
Fibrates may be considered for patients with mixed hyperlipidemia, especially when triglycerides are elevated, as recommended by the European Heart Journal 4, 5

The goal of therapy should be to achieve ≥50% reduction in LDL-C from baseline or reach target LDL-C levels based on cardiovascular risk, according to the Mayo Clinic Proceedings 6, 4
For very high-risk patients, target LDL-C should be low, as recommended by the Mayo Clinic Proceedings 4, 3
For high-risk patients, target LDL-C should be low, according to the Mayo Clinic Proceedings 4, 3
Lipid levels should be assessed 4-12 weeks after initiating therapy to evaluate response, as recommended by the Diabetes Care journal 7, 1

For patients with established cardiovascular disease who cannot tolerate statins, combination therapy with multiple non-statin agents may be necessary to achieve LDL-C goals, as recommended by the journal Drugs 8

Before completely abandoning statin therapy, consider sequential trials of different statins or alternative dosing strategies, as recommended by the Diabetes Care journal and the American College of Cardiology 7, 1
Combination of fibrates with other lipid-lowering therapies increases the risk of myopathy and requires careful monitoring, according to the European Heart Journal and the Diabetes Care journal 5, 7
Lifestyle modifications remain essential and should be continued alongside pharmacological therapy, as recommended by the Mayo Clinic Proceedings and the American College of Cardiology 4, 1